Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
100% free, unsubscribe anytime.
Regeneron rose 13.3% on the quarter, and both Friday biotech IPO debuts broke.
Lilly raised its year to $91 to 92 billion, and Merck's quarter passed the week's test.
Boston Scientific cut guidance a third time, and Biogen returned to growth and fell 3.4%.
Savolitinib made the NEJM, Novartis raised its year, and BioNTech's HER2 ADC won small.
Amgen got paid for a new standard, Summit did not, and Anthropic filed to IPO.
Divarasib beat the approved KRAS drugs head to head, Moderna fell on a win, and Lycia debuted up 66.7%.
